Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  VBI Vaccines Inc.    VBIV   CA91822J1030

VBI VACCINES INC.

(VBIV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period December 2017 2018 2019 2020 (e) 2021 (e) 2022 (e)
Sales 0,87 3,36 2,22 3,38 4,88 29,0
EBITDA - - - - - -
Operating profit (EBIT) -37,3 -60,4 -52,4 -47,6 -44,2 -28,4
Pre-Tax Profit (EBT) -39,4 -63,6 -54,8 -45,4 -45,4 -32,8
Net income -39,0 -63,6 -54,8 -49,4 -45,5 -48,8
P/E ratio -4,85x -1,65x -3,00x -3,53x -4,11x -3,96x
EPS ( $ ) -0,88 -0,97 -0,46 -0,26 -0,23 -0,24
Dividend per Share (  ) - - - - - -
Yield - - - - - -
Reference price ( $ ) 4,270 1,600 1,380 0,931 0,931 0,931
Announcement Date 02/26/2018
10:02pm
02/25/2019
12:32pm
03/05/2020
01:00pm
- - -
Finances - Leverage
Actuals in  $ Estimates in  $
Fiscal Period December 2017 2018 2019 2020 (e) 2021 (e) 2022 (e)
Debt - - - - - -
Finance 0,00 0,00 0,00 0,00 0,00 0,00
Operating income (EBITDA) - - - - - -
Leverage
(Debt/EBITDA)
- - - - - -
Capital Expenditure 0,64 5,99 3,67 1,35 0,90 0,70
Free Cash Flow (FCF) - - -51,4 -36,8 -43,8 -68,9
Book Value Per Share (BVPS) (  ) - - - - - -
Cash Flow per Share (  ) - - - - - -
Announcement Date - - -
Balance Sheet Analysis
Financial data source
© 2020 S&P Global Market Intelligence
Financial Ratios

Size 2020e 2021e
Capitalization 166 M $ -
Valuation 2020e 2021e
P/E ratio (Price / EPS) -3,53x -4,11x
Capitalization / Revenue 49,0x 34,0x
Yield (DPS / Price) - -
Price to book (Price / BVPS) - -
Profitability 2020e 2021e
Operating Margin (EBIT / Sales) -1 408% -906%
Operating Leverage (Delta EBIT / Delta Sales) 0,17x 0,16x
Net Margin (Net Profit / Revenue) -1 460% -933%
ROA (Net Profit / Asset) - -
ROE (Net Profit / Equities) - -
Rate of Dividend - -
Balance Sheet Analysis 2020e 2021e
CAPEX / Sales   39,9% 18,4%
Cash Flow / Sales - -
Capital Intensity (Assets / Sales) - -
Financial Leverage (Net Debt / EBITDA) - -
EPS & Dividend